Additional Title:
Director of Clinical Operations, Division of General & Oncologic Surgery
Email:
Location:
Suite 600
Phone (Primary):
410-328-7320
Fax:
410-328-5919
Dr. Hanna is a surgical oncologist and clinical researcher who specializes in the treatment of gastrointestinal cancers and sarcoma. He is known for his advanced surgical skills to treat patients with complex/advanced/recurrent gastrointestinal cancers and particularly those with diffuse peritoneal metastases.
He received his medical degree from Ain Shams University School of Medicine in Cairo, Egypt. He completed his residency in general surgery at St. Elisabeth’s Medical Center, Tufts University School of Medicine in Boston, MA and a fellowship in surgical oncology at University of Chicago, Pritzker School of Medicine, Chicago, IL.
He is Professor in the Department of Surgery at the University of Maryland School of Medicine and currently serves as the Director of Clinical Operations, Division of General & Oncologic Surgery. Dr. Hanna has published more than 100 peer reviewed scientific articles, 13 book chapters, and has lectured throughout the United States and in other countries. He serves on the Editorial board of Annals of Surgical Oncology, Section of Gastrointestinal Oncology and PLOS ONE. His clinical research is focused on treatment outcomes in GI cancers. His laboratory research collaboration focuses on developing personalized approaches to targeted therapy for gastrointestinal malignancies and the role of the tumor microenvironment in tumor growth and metastasis.
Dr. Hanna is a Fellow of the American College of Surgeons and the Society of Surgical Oncology. He is a member of the Society of University Surgeons, the American Society of Clinical Oncology, and the American Academy on Communications in Healthcare. He is currently the Chair of the International Relationship Committee of the ACS and the Treasurer of the Maryland Chapter of the ACS. Dr. Hanna is an Expert Panel Member for the AJCC Cancer Staging System of the Lower GI Tract. He is a committee member of the Colorectal Cancer Disease site working group, Society of Surgical Oncology and serves as a Consultant for the Complex General Surgical Oncology Continuous Certification Assessment, American Board of Surgery.
His clinical expertise includes:
Dr. Hanna is listed in the top 1% of Top Doctors by the US News and World report and repeatedly as Baltimore Magazine Top Doc in Surgical Oncology and Colorectal Surgery.
Below is a list of my highlighted publications. For a complete List of my published work refer to NIH's My Bibliography.
Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, Toledano A, Hellman S, Kufe DW, Weichselbaum RR. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med. 1995 Aug;1(8):786-91. PubMed PMID: 7585181.
Hanna NN, Hallahan DE, Wayne JD, Weischselbaum RR. Modification of the Radiation Response by the Administration of Exogenous Genes. Semin Radiat Oncol. 1996 Oct;6(4):321-328. PubMed PMID: 10717189.
Mauceri HJ, Hanna NN, Wayne JD, Hallahan DE, Hellman S, Weichselbaum RR. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res. 1996 Oct 1;56(19):4311-4. PubMed PMID: 8813113
Hanna NN, Mauceri HJ, Wayne JD, Hallahan DE, Kufe DW, Weichselbaum RR. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res. 1997 Oct 1;57(19):4205-9. PubMed PMID: 9331076.
Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998 Jul 16;394(6690):287-91. PubMed PMID: 9685160.
Hanna NN, Seetharam S, Mauceri HJ, Beckett MA, Jaskowiak NT, Salloum RM, Hari D, Dhanabal M, Ramchandran R, Kalluri R, Sukhatme VP, Kufe DW, Weichselbaum RR. Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J. 2000 Sep-Oct;6(5):287-93. PubMed PMID: 11079167.
Mohiuddin M, Kudrimoti M, Regine WF, McGrath PC, Hanna N, John W. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: a phase I study. Cancer J. 2002 May-Jun;8(3):255-62. PubMed PMID: 12074325
Hanna NN, Guillem J, Dosoretz A, Steckelman E, Minsky BD, Cohen AM. Intraoperative parasympathetic nerve stimulation with tumescence monitoring during total mesorectal excision for rectal cancer. J Am Coll Surg. 2002 Oct;195(4):506-12. PubMed PMID: 12375756.
Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D, Weichselbaum R, Hanna N. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol. 2004 Feb 15;22(4):592-601. Epub 2004 Jan 15. PubMed PMID: 14726502.
Mohiuddin M, Winter K, Mitchell E, Hanna N, Yuen A, Nichols C, Shane R, Hayostek C, Willett C; Radiation Therapy Oncology Group Trial 0012. Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol. 2006 Feb 1;24(4):650-5. PubMed PMID: 16446336
Turner PL, Ilano AG, Zhu Y, Johnson SB, Hanna N. ACS-NSQIP criteria are associated with APACHE severity and outcomes in critically ill surgical patients. J Am Coll Surg. 2011 Mar;212(3):287-94. doi: 10.1016/j.jamcollsurg.2010.12.011. PubMed PMID: 21356486.
Hanna NN, Onukwugha E, Choti MA, Davidoff AJ, Zuckerman IH, Hsu VD, Mullins CD. Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using surveillance, epidemiology and end results (SEER)-Medicare data. Colorectal Dis. 2012 Jan;14(1):48-55. doi: 10.1111/j.1463-1318.2011.02545.x. PubMed PMID: 21689262.
Hanna N, Ohana P, Konikoff FM, Leichtmann G, Hubert A, Appelbaum L, Kopelman Y, Czerniak A, Hochberg A. Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer. Cancer Gene Ther. 2012 Jun;19(6):374-81. doi: 10.1038/cgt.2012.10. Epub 2012 Apr 13. PubMed PMID: 22498722.
Turner KM, Hanna NN, Zhu Y, Jain A, Kesmodel SB, Switzer RA, Taylor LM, Richard Alexander H Jr. Assessment of neoadjuvant chemotherapy on operative parameters and outcome in patients with peritoneal dissemination from high-grade appendiceal cancer. Ann Surg Oncol. 2013 Apr;20(4):1068-73. doi: 10.1245/s10434-012-2789-1. Epub 2013 Mar 2. PubMed PMID: 23456383.
Zhang G, He P, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Hanna N, Alexander HR, Hussain SP. FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer. Cancer Res. 2013 Sep 1;73(17):5416-25. doi: 10.1158/0008-5472.CAN-13-0362. Epub 2013 Jun 25. PubMed PMID: 23801748; PubMed Central PMCID: PMC3766408.
Zhang G, He P, Tan H, Budhu A, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Maitra A, Hanna N, Alexander HR, Hussain SP. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res. 2013 Sep 15;19(18):4983-93. doi: 10.1158/1078-0432.CCR-13-0209. Epub 2013 Aug 5. PubMed PMID: 23918603; PubMed Central PMCID: PMC3778077.
Asare EA, Compton CC, Hanna NN, Kosinski LA, Washington MK, Kakar S, Weiser MR, Overman MJ. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base. Cancer. 2016 Jan 15;122(2):213-21. Epub 2015 Oct 27. PMID: 26506400
Wang J, Yang S, He P, Schetter A, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Gaida MM,Hanna N, Alexander HR, Hussain SP. Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer. Clin Cancer Res. 2016 Dec 15;22(24):5992-6001. Epub 2016 Jul 8.PMID: 27401251
The Chicago Consensus on Peritoneal Surface Malignancies: Management of Desmoplastic Small Round Cell Tumor, Breast, and Gastrointestinal Stromal Tumors. Ann Surg Oncol. 2020 Jun;27(6):1793-1797. doi: 10.1245/s10434-020-08319-7. Epub 2020 Apr 13. PubMed PMID: 32285268.
Nathenson MJ, Barysauskas CM, Nathenson RA, Regine WF, Hanna N, Sausville E. Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma. World J Surg Oncol. 2018 Oct 11;16(1):203.
Max Seaton, Andrew Hanna, Cherif Boutros and Nader Hanna. Adjuvant therapy for pancreatic body or tail adenocarcinoma: a study of the National Cancer Database. Ther Adv Med Oncol. 2019 May 3;11:175
Complete List of Published Work in My Bibliography
The focus of my clinical research includes population studies of treatment outcomes in GI malignancies, development of a post-operative clinical care pathway following major gastrointestinal cancer surgery; identifying predictors of recurrence and survival in patients undergoing CRS and HIPEC, identification of factors that correlate with post-operative outcome and complications following CRS and HIPEC.
Even though I currently have no independent laboratory, I continue to actively collaborate with several scientist both within the University of Maryland, other universities and the NIH. The focus of my laboratory research collaboration includes developing a personalized approach to targeted therapy for gastrointestinal malignancies and the role of the tumor microenvironment in tumor growth and metastasis.
Comprehensive Evaluation, Diagnosis and Treatment of Colorectal, Pancreatic, Hepatobiliary, Esophageal, Gastric, Peritoneal Surface Malignancies, adrenal tumors and Sarcoma.
Advanced Robotic/Laparoscopic minimally invasive surgery including:
Cytoreductive Surgery and HIPEC for abdominal carcinomatosis
Update Your Profile